Erin Dean
YOU?
Author Swipe
View article: Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma
Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma Open
Introduction Serum soluble B-cell maturation antigen (sBCMA) has been shown to correspond to high disease burden in uncontrolled Multiple Myeloma (MM). However, it has not been extensively evaluated as a biomarker of minimal/measurable res…
View article: Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma Open
View article: Prompt Autologous Hematopoietic Stem Cell Transplant in Patients With Large B‐Cell Lymphoma Is Associated With Lower Rates of Progression of Disease Prior to Transplant
Prompt Autologous Hematopoietic Stem Cell Transplant in Patients With Large B‐Cell Lymphoma Is Associated With Lower Rates of Progression of Disease Prior to Transplant Open
Introduction To ensure response is preserved, it is common practice to continue chemotherapy in patients with large B‐cell lymphoma (LBCL) awaiting autologous hematopoietic stem cell transplant (HSCT), even after they have achieved complet…
View article: 427 | MONITORING CIRUCLATING TUMOR DNA IMPROVES EARLY RELAPSE DETECTION AFTER STANDARD OF CARE 2L+ AXI‐CEL IN LBCL: A PROSPECTIVE STUDY
427 | MONITORING CIRUCLATING TUMOR DNA IMPROVES EARLY RELAPSE DETECTION AFTER STANDARD OF CARE 2L+ AXI‐CEL IN LBCL: A PROSPECTIVE STUDY Open
View article: Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT
Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT Open
View article: Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy
Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy Open
Background Relapsed and refractory Diffuse large B cell lymphoma (DLBCL) can be successfully treated with axicabtagene ciloleucel (axi-cel), a CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy. Diagnostic image-base…
View article: Figure S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S1 shows the serum markers associated with severe CRS and ICANS
View article: Table S6 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S6 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S6: Clinical outcomes of high-risk patients
View article: Figure S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S3 shows that prophylactic steroids do not improve efficacy outcomes in high risk patients
View article: Table S6 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S6 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S6: Clinical outcomes of high-risk patients
View article: Figure S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S3 shows that prophylactic steroids do not improve efficacy outcomes in high risk patients
View article: Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S2 shows the optimal CRP (A) and ferritin (B) cut offs for overall survival
View article: Figure S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S1 shows the serum markers associated with severe CRS and ICANS
View article: Table S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S1 shows a multivariable analysis of grade >2 ICANS using baseline CRP and Ferritin as continuous variables.
View article: Table S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S3 shows the Multivariable Cox Regression analysis of overall (A) and progression free survival (B) using CRP and Ferritin risk categories
View article: Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S5 shows baseline patient and tumor characteristics in high risk patients
View article: Table S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S2 shows Multivariable analysis of grade >2 ICANS across the three risk groups.
View article: Table S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S4: Baseline patient and tumor characteristics in the validation cohorts
View article: Table S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S4: Baseline patient and tumor characteristics in the validation cohorts
View article: Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Figure S2 shows the optimal CRP (A) and ferritin (B) cut offs for overall survival
View article: Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and in…
View article: Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and in…
View article: Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S5 shows baseline patient and tumor characteristics in high risk patients
View article: Table S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S3 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S3 shows the Multivariable Cox Regression analysis of overall (A) and progression free survival (B) using CRP and Ferritin risk categories
View article: Table S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S1 shows a multivariable analysis of grade >2 ICANS using baseline CRP and Ferritin as continuous variables.
View article: Table S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
Table S2 shows Multivariable analysis of grade >2 ICANS across the three risk groups.
View article: Working in safeguarding: the consultant paediatrician
Working in safeguarding: the consultant paediatrician Open
View article: Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report Open
Introduction: Neurological toxicity following chimeric antigen receptor T-cell infusion, termed immune cell-associated neurotoxicity syndrome (ICANS), is a common and limiting factor in the expansion of this promising treatme…
View article: Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma Open
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and in…
View article: Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood.</i> 2022;140(5):491-503.
Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood.</i> 2022;140(5):491-503. Open